Main Products/ Services/ Pipelines & Platforms
OBI's novel cancer therapeutics: - Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine) - OBI-833 (Globo H cancer vaccine) - OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme) - OBI-992 (TROP2 ADC, cysteine platform) - OBI-902 (TROP2 ADC, GlycOBI platform) - OBI-904 (Nectin4 ADC, GlycOBI platform) - OBI-905 (HER2 ADC, GlycOBI platform)
OBI’s proprietary ADC enabling technologies to help customers creating novel and optimized ADCs. - GlycOBI® - EndoSymeOBI® - HyprOBI™ - ThiOBI®
OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (4174.TWO). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC enabling technologies and has a novel oncology portfolio listed above.
Business Interests
Out-Licensing, Collaborative R&D, Co-Development, Strategic Alliance
Contact Info
Celeste Chuang
Director, Business Development
+886-2-26558799 ext 217
cchuang@obipharma.com